Wells Fargo initiated coverage of Centessa (CNTA) with an Overweight rating and $31 price target Near-term OX2R, orexin-2 receptor, agonism data in narcolepsy type-1,2, and idiopathic hypersomnia, or IH, offer meaningful catalysts for Centessa, the analyst tells investors in a research note. The company’s NT2/IH data expected this year should have a greater capacity to re-rate shares, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Centessa resumed with an Outperform at Oppenheimer
- Buy Rating on Centessa Pharmaceuticals Driven by Promising Drug Candidates and Strong Financial Position
- Centessa Pharmaceuticals: Buy Rating Driven by ORX750’s Promising Efficacy and Acquisition Potential
- Centessa Pharmaceuticals: Promising Pipeline Developments and Strategic Flexibility Drive Buy Rating